Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tranylcypromine sulfate
Drug ID BADD_D02263
Description A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).
Indications and Usage For the treatment of major depressive episode without melancholia.
Marketing Status approved; investigational
ATC Code N06AF04
DrugBank ID DB00752
KEGG ID D00826
MeSH ID D014191
PubChem ID 25267092
TTD Drug ID D0H0HJ
NDC Product Code 59212-447; 49884-032; 46204-0130; 64380-176; 64330-090; 58159-082; 0591-5590
UNII 7ZAT6ES870
Synonyms Tranylcypromine | trans-2-Phenylcyclopropylamine | trans 2 Phenylcyclopropylamine | Tranylcypromine Sulfate | Sulfate, Tranylcypromine | Jatrosom | Transamine | Parnate
Chemical Information
Molecular Formula C18H24N2O4S
CAS Registry Number 13492-01-8
SMILES C1C(C1N)C2=CC=CC=C2.C1C(C1N)C2=CC=CC=C2.OS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agranulocytosis01.02.03.001--Not Available
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Asthenia08.01.01.001--Not Available
Chills15.05.03.016; 08.01.09.001--
Constipation07.02.02.001--
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dry mouth07.06.01.002--
Ejaculation failure21.03.01.003--Not Available
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Headache17.14.01.001--
Hepatitis09.01.07.004--Not Available
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Leukopenia01.02.02.001--Not Available
Muscle spasms15.05.03.004--
Myoclonus17.02.05.008--Not Available
Nausea07.01.07.001--
Oedema14.05.06.010; 08.01.07.006--Not Available
Palpitations02.11.04.012--
Paraesthesia17.02.06.005; 23.03.03.094--
Rash23.03.13.001--Not Available
Restlessness19.11.02.002; 17.02.05.021--
Somnolence19.02.05.003; 17.02.04.006--
Tachycardia02.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tremor17.01.06.002--
The 1th Page    1 2    Next   Last    Total 2 Pages